Class summary at a glance.

Every drug in the Sodium-Glucose Cotransporter 2 Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 7tracked in Part D
CY24 Part D spend: $18.49Bcombined across class
Total Rx claims: 17.9M5.0M unique beneficiaries
Generic mfrs (active): 0across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Empagliflozin

Brand: JARDIANCE · 17.9M Part D claims (CY24) · 5.0M beneficiaries · First FDA approval: 2014-08-01

Brand-only (no generics) 0 plans require PA

Low NADAC$11.20

→

Avg plan cost$11.20

Part D spend $18.48B 1× spread, current vs floor

Class share

100%

of class CY24 spend

View profile →

Sotagliflozin

Brand: INPEFA · 12K Part D claims (CY24) · 3K beneficiaries · First FDA approval: 2023-05-26

Brand-only (no generics) 36 plans require PA

Low NADAC$20.34

→

Avg plan cost$20.34

Part D spend $9.3M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Bexagliflozin

Brand: BRENZAVVY · — Part D claims (CY24) · First FDA approval: 2023-01-20

Brand-only (no generics)

Low NADAC—

→

Avg plan cost—

Part D spend —

Class share

of class CY24 spend

View profile →

Empagliflozin and Linagliptin

Brand: Glyxambi · — Part D claims (CY24) · First FDA approval: 2015-01-30

Brand-only (no generics) 2 plans require PA

Low NADAC$11.19

→

Avg plan cost$11.21

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Empagliflozin and Metformin

Brand: Synjardy · — Part D claims (CY24) · First FDA approval: 2015-08-26

Brand-only (no generics) 0 plans require PA

Low NADAC$5.60

→

Avg plan cost$5.61

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Empagliflozin, Linagliptin, Metformin

Brand: Trijardy XR · — Part D claims (CY24) · First FDA approval: 2020-04-23

Brand-only (no generics) 4 plans require PA

Low NADAC$5.62

→

Avg plan cost$8.44

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Empagliflozin, Metformin

Brand: Synjardy · — Part D claims (CY24) · First FDA approval: 2016-12-10

Brand-only (no generics) 0 plans require PA

Low NADAC$5.59

→

Avg plan cost$8.41

Part D spend — 2× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.